Welcome to our dedicated page for CEL SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CEL-SCI Corporation filings document a clinical-stage biotechnology issuer funding the development of Multikine through registered securities offerings and reporting material corporate actions. Registration statements and prospectus-related filings describe common stock issuance capacity, use of proceeds for Multikine development, working capital, risk factors, operating and financial results, and the company's capital structure.
Current reports on Form 8-K record placement agency agreements, closed equity offerings, and amendments to the company's Shareholder Rights Agreement, including modifications to security-holder rights. The filing record also provides formal disclosure around governance, material agreements, and financing terms tied to CEL-SCI's cancer immunotherapy development business.
CEL-SCI Corporation has called its 2026 annual shareholder meeting for August 14, 2026 in Vienna, Virginia. Shareholders will elect directors, vote on a new 2026 Non-Qualified Stock Option Plan covering up to 2,600,000 shares, and a 2026 Stock Bonus Plan covering up to 400,000 shares.
They will also cast non-binding advisory votes on executive compensation and how often to hold future say-on-pay votes, with the Board recommending every three years, and will vote on ratifying BDO USA, P.C. as independent auditor for the fiscal year ending September 30, 2026. CEL-SCI reports 17,477,144 common shares outstanding as of June 18, 2026 and discloses detailed executive pay, including 2025 CEO total compensation of $919,854.
TALOR EYAL reported acquisition or exercise transactions in this Form 4 filing.
CEL SCI CORP Chief Scientific Officer receives stock grant. Chief Scientific Officer Talor Eyal was granted 2,307 shares of CEL SCI CORP common stock at a reference price of $1.04 per share. After this compensation-related award, Eyal directly holds a total of 9,318 common shares.
CEL SCI CORP Chief Financial Officer Patricia B. Prichep received a grant or award of 4,125 shares of common stock on June 30, 2026 at a reported value of $1.04 per share. After this acquisition, she directly owns 17,489 shares of the company’s common stock.
CEL-SCI Corp Chief Executive Officer Geert R. Kersten reported a compensation-related acquisition of 5,192 shares of common stock at $1.04 per share. Following this grant, he directly holds 216,142 common shares and indirectly holds 311,547 common shares as trustee.
CEL-SCI Corporation has priced a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, for expected gross proceeds of $2.5 million before fees and expenses. The offering is expected to close on June 16, 2026, subject to customary conditions.
The company plans to use the cash to continue developing its investigational cancer immunotherapy Multikine, as well as for general corporate purposes and working capital. The shares are being sold under an effective Form S-3 shelf registration, with ThinkEquity acting as sole placement agent.
CEL-SCI Corporation is offering 2,500,000 shares of common stock at $1.00 per share on a best-efforts basis. The offering is expected to deliver gross proceeds of $2,500,000 and estimated net proceeds of approximately $2.2 million to fund continued development of Multikine and for general corporate purposes. The prospectus supplement notes there is no minimum offering requirement, placement agent fees of $0.07 per share, and that closing is expected on or about June 16, 2026. The company reported 14,977,144 shares outstanding prior to this offering (as of June 12, 2026), and anticipates 17,477,144 shares outstanding after this offering.
CEL SCI CORP director and CEO Geert Kersten reported a significant insider purchase through a related trust. On May 14, 2026, the de Clara Trust, for which Mr. Kersten serves as trustee, bought 300,000 shares of restricted common stock directly from the company at $1.20 per share, equal to the most recent closing price on May 13, 2026.
After this transaction, Mr. Kersten is shown with 210,950 common shares held directly and 311,547 common shares held indirectly as trustee of the de Clara Trust. The filing shows no derivative securities remaining after this activity.